Statistik Asas
| LEI | 529900EO9LUTFMZ7FF90 |
| CIK | 1088856 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Corcept Therapeutics Incorporated
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update EXHIBIT 99.1 Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update •Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 •Modified 2025 revenue guidance of $850 – $900 million •Net income of $35.1 million, compared to $35.5 million in second quarter 2024 •Cash and investments of $515.0 million at June 30, 2025 •Acquired $115.4 million |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 31, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Com |
|
| July 14, 2025 |
Exhibit 99.1 CONTACT: Investor inquiries: [email protected] Media inquiries: [email protected] www.corcept.com Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer REDWOOD CITY, Calif., (July 14, 2025) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of m |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 14, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Com |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 June 10, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or or |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| May 5, 2025 |
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE •Revenue of $157.2 million, compared to $146.8 million in first quarter 2024 •Reiterated 2025 revenue guidance of $900 – $950 million •Net income per common share (diluted) of $0.17, compared to $0.25 in first quarter 2024 •Cash and investments of $570.8 million as of March 31, 2025 REDWOOD CI |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 5, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Commi |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 31, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Co |
|
| March 31, 2025 |
Exhibit 99.1 CONTACT: Investor inquiries: [email protected] Media inquiries: [email protected] www.corcept.com PRIMARY ENDPOINT MET IN CORCEPT’S PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER • Relacorilant plus nab-paclitaxel improved progression-free and overall survival and did not increase side effect burden • Results will support a New D |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 3, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Com |
|
| March 3, 2025 |
Exhibit 99.1 CONTACT: Investor inquiries: [email protected] Media inquiries: [email protected] www.corcept.com FDA FILES CORCEPT’S NEW DRUG APPLICATION FOR RELACORILANT AS TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025 REDWOOD CITY, Calif., (March 3, 2025) — Corcept Therapeutics Incorporated (NASDAQ: C |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 26, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCO |
|
| February 26, 2025 |
EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE •2024 revenue of $675.0 million, a 40 percent increase over 2023 •2025 revenue guidance of $900 – $950 million •2024 net income of $141.2 million, a 33 percent increase over 2023 •Cash and investments of $603.2 million as of December 31, 2024 REDWOOD CITY, Calif., ( |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 30, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) |
|
| December 30, 2024 |
Exhibit 99.1 CONTACT: Investor inquiries: [email protected] Media inquiries: [email protected] www.corcept.com CORCEPT SUBMITS NEW DRUG APPLICATION FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM REDWOOD CITY, Calif., (December 30, 2024) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to |
|
| October 30, 2024 |
EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS, POSITIVE RESULTS FROM PHASE 3 GRADIENT TRIAL IN PATIENTS WITH CUSHING’S SYNDROME AND PROVIDES CORPORATE UPDATE •Revenue of $182.5 million, a 48 percent increase over the same period in 2023 •Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million •Net income per common share of $0.41 (diluted), |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 30, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) ( |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEU |
|
| July 29, 2024 |
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (July 29, 2024) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cor |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 29, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Com |
|
| July 29, 2024 |
Exhibit 10.1 TENTH AMENDMENT TO LEASE THIS TENTH AMENDMENT TO LEASE (the "Tenth Amendment") is made and entered into as of May 13, 2024, by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the "Lease"), |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Corcept Therapeutics Incorporated (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| May 31, 2024 |
Exhibit 4.4 CORCEPT THERAPEUTICS, INCORPORATED 2024 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE Corcept Therapeutics, Incorporated, a Delaware corporation (the “Company”), pursuant to its 2024 Incentive Award Plan (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of shares of the Company’s Common Stock set forth below (the “Shares”) subject to all o |
|
| May 31, 2024 |
Exhibit 4.3 CORCEPT THERAPEUTICS INCORPORATED 2024 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Corcept Therapeutics Incorporated, a Delaware corporation, (the “Company”), pursuant to its 2024 Incentive Award Plan (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of shares of the Company’s common stock, par value $0.001 (“Stock”), set forth b |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 May 17, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or org |
|
| May 1, 2024 |
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (May 1, 2024) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortis |
|
| May 1, 2024 |
[Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. |
|
| May 1, 2024 |
NINTH AMENDMENT TO LEASE THIS NINTH AMENDMENT TO LEASE (the "Ninth Amendment") is made and entered into as of March 19, 2024, by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”). |
|
| May 1, 2024 |
[Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 1, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Commi |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 April 12, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or o |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| February 15, 2024 |
Corcept Therapeutics Incorporated Insider Trading Policy CORCEPT THERAPEUTICS INCORPORATED INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Company Securities Purpose This Policy provides guidelines with respect to transactions in the securities of Corcept Therapeutics Incorporated (the “Company”). |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 15, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) |
|
| February 15, 2024 |
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (February 15, 2024) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone |
|
| February 15, 2024 |
Corcept Therapeutics Incorporated Compensation Clawback Polic CORCEPT THERAPEUTICS INCORPORATED COMPENSATION CLAWBACK POLICY Corcept Therapeutics Incorporated (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this Compensation Clawback Policy (this “Policy”), which provides for the recovery of certain Incentive-Based Compensation in the event of an Accounting Restatement (each as defined below). |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCO |
|
| February 14, 2024 |
CORT / Corcept Therapeutics Incorporated / BAKER G LEONARD JR - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Corcept Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 13, 2024 |
CORT / Corcept Therapeutics Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Corcept Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 218352102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| February 12, 2024 |
CORT / Corcept Therapeutics Incorporated / BELANOFF JOSEPH K - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Corcept Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securit |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 January 8, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| January 8, 2024 |
CORCEPT THERAPEUTICS PROVIDES FINANCIAL UPDATE AND ANNOUNCES STOCK REPURCHASE PROGRAM EX-99.1 Exhibit 99.1 CONTACT: Investor inquiries: [email protected] Media inquiries: [email protected] www.corcept.com CORCEPT THERAPEUTICS PROVIDES FINANCIAL UPDATE AND ANNOUNCES STOCK REPURCHASE PROGRAM MENLO PARK, Calif., (January 8, 2024) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe |
|
| January 2, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 January 2, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| January 2, 2024 |
COURT FINDS CORCEPT THERAPEUTICS’ PATENTS NOT INFRINGED EX-99.1 Exhibit 99.1 CONTACT Investor inquiries: [email protected] Media inquiries: [email protected] www.corcept.com COURT FINDS CORCEPT THERAPEUTICS’ PATENTS NOT INFRINGED MENLO PARK, Calif., (January 2, 2024) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, met |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 December 5, 2023 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| December 11, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CORCEPT THERAPEUTICS INCORPORATED a Delaware corporation ARTICLE I STOCKHOLDERS 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date and at such time as designated by resolution of the Board o |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 1, 2023 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) ( |
|
| November 1, 2023 |
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (November 1, 2023) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortiso |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEU |
|
| August 15, 2023 |
August 15, 2023 Mr. Daniel Crawford Ms. Jennifer Zepralka United States Securities and Exchange Commission Division of Corporation Finance Disclosure Review Program 100 F Street, N.E. Washington, D.C. 20549 Re: Corcept Therapeutics Incorporated Definitive Proxy Statement on Schedule 14A Filed April 14, 2023 File No. 000-50679 Dear Mr. Crawford and Ms. Zepralka: On behalf of our client, Corcept The |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 2, 2023 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Co |
|
| August 2, 2023 |
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (August 2, 2023) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol |
|
| August 2, 2023 |
Form of 2012 Incentive Award Plan Restricted Stock Unit Grant Notice and Agreement Exhibit 10.1 CORCEPT THERAPEUTICS INCORPORATED 2012 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Corcept Therapeutics Incorporated, a Delaware corporation, (the “Company”), pursuant to its 2012 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted stock units (“Restricted Stock Units” or “RSU |
|
| August 2, 2023 |
Form of 2012 Incentive Award Plan Restricted Stock Award Grant Notice and Agreement Exhibit 10.2 CORCEPT THERAPEUTICS INCORPORATED 2012 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE Corcept Therapeutics, Incorporated, a Delaware corporation (the “Company”), pursuant to its 2012 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of shares of the Company’s Common Stock set forth below ( |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 May 19, 2023 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or org |
|
| May 24, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION CORCEPT THERAPEUTICS INCORPORATED Corcept Therapeutics Incorporated, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: a. The name of the Corporation is Corcept Therapeutics Incorporated. The original Certificate of Incorporation was filed with the Secretary of |
|
| May 8, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 3, 2023 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Commi |
|
| May 3, 2023 |
Exhibit 10.1 EIGHTH AMENDMENT TO LEASE THIS EIGHTH AMENDMENT TO LEASE (the “Eighth Amendment”) is made and entered into as of April 1, 2023 by and between Exponent Realty, LLC, a Delaware limited liability company (“Landlord”), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the “Lease” |
|
| May 3, 2023 |
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (May 3, 2023) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 5, 2023 |
Corcept Therapeutics Announces Final Results of Tender Offer EX-99.(a)(7) EXHIBIT (a)(7) CONTACT: Corcept Therapeutics Incorporated Investor Relations [email protected] www.corcept.com Corcept Therapeutics Announces Final Results of Tender Offer MENLO PARK, Calif., April 5, 2023 — Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic a |
|
| April 5, 2023 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number of Clas |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 3, 2023 |
Corcept Therapeutics Announces Preliminary Results of Tender Offer EX-99.(a)(6) EXHIBIT (a)(6) CONTACT: Corcept Therapeutics Incorporated Investor Relations [email protected] www.corcept.com Corcept Therapeutics Announces Preliminary Results of Tender Offer MENLO PARK, Calif., April 3, 2023 — Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metab |
|
| April 3, 2023 |
SC TO-I/A 1 d471631dsctoia.htm SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) |
|
| March 7, 2023 |
EX-99.(A)(1)(G) EXHIBIT (a)(1)(G) Notice of Withdrawal For Tender of Shares of Common Stock Pursuant to the Offer to Purchase, Dated March 6, 2023 by Corcept Therapeutics Incorporated Up to 7,500,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $22.00 per Share Nor Less than $19.25 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFT |
|
| March 7, 2023 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number of Class |
|
| March 6, 2023 |
EX-99.(A)(5) EXHIBIT (a)(5) CONTACT: Corcept Therapeutics Incorporated Investor Relations [email protected] www.corcept.com Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock MENLO PARK, Calif., March 6, 2023 —Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development |
|
| March 6, 2023 |
EX-99.(A)(1)(C) EXHIBIT (a)(1)(C) Notice of Guaranteed Delivery For Tender of Shares of Common Stock of Corcept Therapeutics Incorporated THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON MARCH 31, 2023, UNLESS THE OFFER IS EXTENDED OR TERMINATED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATION DATE”). This Notice |
|
| March 6, 2023 |
EX-99.(A)(1)(E) EXHIBIT (a)(1)(E) Offer to Purchase for Cash by Corcept Therapeutics Incorporated Up to 7,500,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $22.00 per Share Nor Less than $19.25 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON MARCH 31, 2023, UNLESS THE OFFER IS EXTENDED OR |
|
| March 6, 2023 |
EX-99.(A)(1)(A) Table of Contents EXHIBIT (a)(1)(A) Offer to Purchase by Corcept Therapeutics Incorporated Up to 7,500,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $22.00 per Share Nor Less than $19.25 per Share CUSIP: 218352102 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON MARCH 31, 2023, UNLESS THE |
|
| March 6, 2023 |
SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number of Class of Securities) Atab |
|
| March 6, 2023 |
EX-99.(A)(1)(B) EXHIBIT (a)(1)(B) Letter of Transmittal For Tender of Shares of Common Stock Pursuant to the Offer to Purchase, Dated March 6, 2023 by Corcept Therapeutics Incorporated Up to 7,500,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $22.00 per Share Nor Less than $19.25 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AF |
|
| March 6, 2023 |
EX-99.(A)(1)(G) EXHIBIT (a)(1)(G) Notice of Withdrawal For Tender of Shares of Common Stock Pursuant to the Offer to Purchase, Dated March 6, 2023 by Corcept Therapeutics Incorporated Up to 7,500,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $19.25 per Share Nor Less than $19.25 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFT |
|
| March 6, 2023 |
EX-99.(A)(1)(F) EXHIBIT (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated March 6, 2023, and the related Letter of Transmittal and Important Instructions and Information. The Offer is being made to all holders of Shares, provided that the |
|
| March 6, 2023 |
EX-FILING FEES 11 d79724dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table SC TO-I (Form Type) Corcept Therapeutics Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 – Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $165,000,000.00(1) 0.00011020 $18,183.00(2) Fees Previously Paid — — — Total Transaction V |
|
| March 6, 2023 |
E-Mail to Employees of Corcept Therapeutics Incorporated Regarding Tender Offer EX-99.(A)(1)(H) EXHIBIT (a)(1)(H) E-Mail to Employees of Corcept Therapeutics Incorporated Regarding Tender Offer In response to your question, on March 6, 2023 we announced a tender offer to purchase up to 7,500,000 shares of our common stock (“Shares”). If you own Shares, you may offer to sell them back to the company through a process known as a “tender offer” that will take place between March |
|
| March 6, 2023 |
EX-99.(A)(1)(D) EXHIBIT (a)(1)(D) Offer to Purchase for Cash by Corcept Therapeutics Incorporated Up to 7,500,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $22.00 per Share Nor Less than $19.25 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON MARCH 31, 2023, UNLESS THE OFFER IS EXTENDED OR |
|
| February 28, 2023 |
EX-99.1 2 exhibit991pressrelease02-2.htm EX-99.1 EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (February 28, 2023) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metab |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCO |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 28, 2023 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) |
|
| February 15, 2023 |
CORT / Corcept Therapeutics Incorporated / BELANOFF JOSEPH K - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Corcept Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securit |
|
| February 14, 2023 |
CORT / Corcept Therapeutics Incorporated / BAKER G LEONARD JR - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Corcept Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 13, 2023 |
EX-99.1 Exhibit 99.1 CONTACT: Corcept Therapeutics Investor Relations [email protected] www.corcept.com CORCEPT THERAPEUTICS ANNOUNCES PRELIMINARY SETTLEMENT OF PURPORTED SECURITIES CLASS ACTION LITIGATION MENLO PARK, Calif. (February 13, 2023) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocri |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 13, 2023 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation o |
|
| February 9, 2023 |
CORT / Corcept Therapeutics Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Corcept Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 218352102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 8, 2022 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| December 8, 2022 |
CORCEPT THERAPEUTICS SETTLES PATENT LITIGATION WITH HIKMA PHARMACEUTICALS EX-99.1 Exhibit 99.1 CONTACT: Corcept Therapeutics Investor Relations [email protected] www.corcept.com CORCEPT THERAPEUTICS SETTLES PATENT LITIGATION WITH HIKMA PHARMACEUTICALS MENLO PARK, Calif. (December 8, 2022) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 3, 2022 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) ( |
|
| November 3, 2022 |
10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Task Order Number One to Master Services Agreement Between Corcept Therapeutics Inc. and Optime Care. Inc. This Task Order Number One (the ?Task Order?) is effective as o |
|
| November 3, 2022 |
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (November 3, 2022) ? Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone corti |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEU |
|
| November 3, 2022 |
10.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT TO DISTRIBUTION SERVICES AGREEMENT This Amendment to Distribution Services Agreement (this ?Amendment?), effective as of August 1, 2022 (the ?Amendment Effectiv |
|
| November 3, 2022 |
10.4 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 2 TO DISTRIBUTION SERVICES AGREEMENT This Amendment No. 2 to Distribution Services Agreement (this ?Amendment?), effective as of September 16, 2022 (the ?Am |
|
| November 3, 2022 |
10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. DISTRIBUTION SERVICES AGREEMENT This Distribution Services Agreement (?Agreement?), effective as of August 4, 2017 (the ?Effective Date?), is made by and between Corcept |
|
| September 22, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 16, 2022 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) |
|
| August 4, 2022 |
Form of 2012 Incentive Award Plan Restricted Stock Unit Grant Notice and Agreement Exhibit 10.1 CORCEPT THERAPEUTICS INCORPORATED 2012 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Corcept Therapeutics Incorporated, a Delaware corporation, (the ?Company?), pursuant to its 2012 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of restricted stock units (?Restricted Stock Units? or ?RSU |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| August 4, 2022 |
Form of 2012 Incentive Award Plan Restricted Stock Award Grant Notice and Agreement Exhibit 10.2 CORCEPT THERAPEUTICS INCORPORATED 2012 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE Corcept Therapeutics, Incorporated, a Delaware corporation (the ?Company?), pursuant to its 2012 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?) the number of shares of the Company?s Common Stock set forth below ( |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 3, 2022 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Co |
|
| August 3, 2022 |
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (August 3, 2022) ? Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortis |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 31, 2022 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or org |
|
| May 5, 2022 |
Exhibit 10.1 SEVENTH AMENDMENT TO LEASE THIS SEVENTH AMENDMENT TO LEASE (the "Seventh Amendment") is made and entered into as of March 18, 2022 by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the "Le |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 5, 2022 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or orga |
|
| May 5, 2022 |
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (May 5, 2022) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 9, 2022 |
CORT / Corcept Therapeutics Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Corcept Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 218352102 Date of Event Which Requires Filing of this Statement: February 28, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCO |
|
| February 15, 2022 |
Employment offer letter to William Guyer, dated July 2, 2021. Exhibit 10.1 William Guyer Re: Offer of Employment at Corcept Therapeutics Incorporated Dear Bill: We are very pleased to invite you to join Corcept Therapeutics Incorporated (the ?Company?) in the role of Chief Development Officer, contingent upon the satisfactory completion of a background check. Duties and Responsibilities. Your initial assignment will be as Chief Development Officer reporting |
|
| February 15, 2022 |
EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2021 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (February 15, 2022) ? Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect |
|
| February 15, 2022 |
As filed with the Securities and Exchange Commission on February 15, 2022 As filed with the Securities and Exchange Commission on February 15, 2022 Registration No. |
|
| February 15, 2022 |
Exhibit 10.2 SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (?Agreement?) dated as of February 9, 2022 (the ?Effective Date?) is entered into by and between William Guyer, Chief Development Officer (?OFFICER?) and Corcept Therapeutics Incorporated, a Delaware corporation (the ?Company?). WITNESSETH: WHEREAS, OFFICER is a senior executive of the Company and |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 15, 2022 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation o |
|
| February 15, 2022 |
Exhibit 10.14 CORCEPT THERAPEUTICS INCORPORATED 2012 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Corcept Therapeutics Incorporated, a Delaware corporation, (the ?Company?), pursuant to its 2012 Incentive Award Plan, as it may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an option to purchase the number of shares of the Company?s common sto |
|
| February 15, 2022 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES FORM S-8 (Form Type) CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common S |
|
| February 14, 2022 |
CORT / Corcept Therapeutics Incorporated / BAKER G LEONARD JR - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corcept Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 11, 2022 |
CORT / Corcept Therapeutics Incorporated / BELANOFF JOSEPH K - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Corcept Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securit |
|
| February 9, 2022 |
CORT / Corcept Therapeutics Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0660-corcepttherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Corcept Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 218352102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number of Class of Secur |
|
| December 20, 2021 |
Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer EXHIBIT (a)(9) CONTACT: Corcept Therapeutics Investor Relations [email protected] www.corcept.com Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer MENLO PARK, Calif., December 20, 2021 ? Corcept Therapeutics Incorporated (NASDAQ: CORT) (?Corcept?), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psy |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number of Class of Secur |
|
| December 16, 2021 |
Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer EXHIBIT (a)(8) CONTACT: Corcept Therapeutics Investor Relations [email protected] www.corcept.com Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer MENLO PARK, Calif., December 16, 2021 ? Corcept Therapeutics Incorporated (NASDAQ: CORT) (?Corcept?), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic a |
|
| December 15, 2021 |
Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares EX-99.A.7 2 d205842dex99a7.htm EX-99.A.7 EXHIBIT (a)(7) CONTACT: Corcept Therapeutics Investor Relations [email protected] www.corcept.com Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares MENLO PARK, Calif., December 15, 2021 — Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of dr |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number of Class of Secur |
|
| December 8, 2021 |
Corcept Therapeutics Announces Extension of Previously Announced Tender Offer EXHIBIT 99.1 CONTACT: Corcept Therapeutics Incorporated Investor Relations [email protected] www.corcept.com Corcept Therapeutics Announces Extension of Previously Announced Tender Offer MENLO PARK, Calif., December 8, 2021 ? Corcept Therapeutics Incorporated (NASDAQ: CORT) (?Corcept?) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic an |
|
| December 8, 2021 |
Corcept Therapeutics Announces Extension of Previously Announced Tender Offer EXHIBIT (a)(6) CONTACT: Corcept Therapeutics Incorporated Investor Relations ir@corcept. |
|
| December 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 15, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation o |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number of Class of Secur |
|
| November 15, 2021 |
Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park, California 94025 CORRESP 1 filename1.htm Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park, California 94025 November 15, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington D.C. 20549 Attention: Li Xiao Angela Connell Re: Corcept Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 202 |
|
| November 15, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCE |
|
| November 8, 2021 |
Table of Contents EXHIBIT (a)(1)(A) Offer to Purchase by Corcept Therapeutics Incorporated Up to 10,000,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $23. |
|
| November 8, 2021 |
EXHIBIT (a)(1)(D) Offer to Purchase for Cash by Corcept Therapeutics Incorporated Up to 10,000,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $23. |
|
| November 8, 2021 |
EXHIBIT (a)(1)(G) Notice of Withdrawal For Tender of Shares of Common Stock Pursuant to the Offer to Purchase, Dated November 8, 2021 by Corcept Therapeutics Incorporated Up to 10,000,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $23. |
|
| November 8, 2021 |
EXHIBIT (a)(1)(E) Offer to Purchase for Cash by Corcept Therapeutics Incorporated Up to 10,000,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $23. |
|
| November 8, 2021 |
E-Mail to Employees of Corcept Therapeutics Incorporated Regarding Tender Offer EXHIBIT (a)(1)(H) E-Mail to Employees of Corcept Therapeutics Incorporated Regarding Tender Offer In response to your question, on November 8, 2021 we announced a tender offer to purchase up to 10 million shares of our common stock (?Shares?). |
|
| November 8, 2021 |
EXHIBIT (a)(5) CONTACT: Corcept Therapeutics Incorporated Investor Relations ir@corcept. |
|
| November 8, 2021 |
SC TO-I 1 d228455dsctoi.htm SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Corcept Therapeutics Incorporated (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number |
|
| November 8, 2021 |
EXHIBIT (a)(1)(B) Letter of Transmittal For Tender of Shares of Common Stock Pursuant to the Offer to Purchase, Dated November 8, 2021 by Corcept Therapeutics Incorporated Up to 10,000,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $23. |
|
| November 8, 2021 |
EXHIBIT (a)(1)(C) Notice of Guaranteed Delivery For Tender of Shares of Common Stock of Corcept Therapeutics Incorporated THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFTER 11:59 P. |
|
| November 8, 2021 |
EXHIBIT (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| November 3, 2021 |
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (November 3, 2021) ? Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today re |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 3, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEU |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 10, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| August 13, 2021 |
EX-10.1 2 d552481dex101.htm EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between Andreas Grauer (“Executive”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day after the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A. Executi |
|
| August 13, 2021 |
WILLIAM GUYER TO JOIN CORCEPT AS CHIEF DEVELOPMENT OFFICER Exhibit 99.1 CONTACT: Investor Relations [email protected] www.corcept.com WILLIAM GUYER TO JOIN CORCEPT AS CHIEF DEVELOPMENT OFFICER MENLO PARK, Calif. (August 12, 2021)?Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone c |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 29, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or or |
|
| July 29, 2021 |
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (July 29, 2021) ? Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today repo |
|
| June 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 15, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or or |
|
| June 15, 2021 |
CORCEPT THERAPEUTICS SETTLES PATENT LITIGATION WITH SUN PHARMACEUTICAL EXHIBIT 99.1 CORCEPT THERAPEUTICS SETTLES PATENT LITIGATION WITH SUN PHARMACEUTICAL MENLO PARK, Calif. (June 15, 2021) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has entered into an agreem |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 9, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or org |
|
| June 10, 2021 |
CORCEPT THERAPEUTICS APPOINTS JOSHUA M. MURRAY TO BOARD OF DIRECTORS EXHIBIT 99.1 CORCEPT THERAPEUTICS APPOINTS JOSHUA M. MURRAY TO BOARD OF DIRECTORS MENLO PARK, Calif. (Jun. 10, 2021) ? Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Mu |
|
| June 2, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 26, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or org |
|
| May 6, 2021 |
Exhibit 10.1 Atabak Mokari December 21, 2020 Re: Offer of Employment at Corcept Therapeutics Incorporated Dear Atabak: We are very pleased to invite you to join Corcept Therapeutics Incorporated (the ?Company?) in the role of Chief Financial Officer, contingent upon the satisfactory completion of a background check. Duties and Responsibilities. Your initial assignment will be as Chief Financial Of |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 6, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or orga |
|
| May 6, 2021 |
CORCEPT THERAPEUTICS PROVIDES CLINICAL UPDATE AND ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS EXHIBIT 99.1 CORCEPT THERAPEUTICS PROVIDES CLINICAL UPDATE AND ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS ?In a 178-patient, controlled, Phase 2 trial, women with platinum resistant ovarian cancer who received relacorilant plus nab-paclitaxel experienced improved progression free survival (PFS) compared to women who received nab-paclitaxel alone, with comparable safety and tolerability; planni |
|
| May 6, 2021 |
Exhibit 10.2 SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (?Agreement?) dated as of March 1, 2021 (the ?Effective Date?) is entered into by and between Atabak Mokari, Chief Financial Officer (?CFO?) and Corcept Therapeutics Incorporated, a Delaware corporation (the ?Company?). WITNESSETH: WHEREAS, CFO is a senior executive of the Company and is expected |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 1, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or or |
|
| March 1, 2021 |
EX-10.1 2 d136427dex101.htm EX-10.1 Exhibit 10.1 Atabak Mokari December 21, 2020 Re: Offer of Employment at Corcept Therapeutics Incorporated Dear Atabak: We are very pleased to invite you to join Corcept Therapeutics Incorporated (the “Company”) in the role of Chief Financial Officer, contingent upon the satisfactory completion of a background check. Duties and Responsibilities. Your initial assi |
|
| March 1, 2021 |
Exhibit 10.2 SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (?Agreement?) dated as of March 1, 2021 (the ?Effective Date?) is entered into by and between Atabak Mokari, Chief Financial Officer (?CFO?) and Corcept Therapeutics Incorporated, a Delaware corporation (the ?Company?). WITNESSETH: WHEREAS, CFO is a senior executive of the Company and is expected |
|
| March 1, 2021 |
Exhibit 99.1 CONTACT: Christopher S. James, MD Director, Investor Relations Corcept Therapeutics 650-684-8725 [email protected] www.corcept.com CORCEPT THERAPEUTICS EXPANDS EXECUTIVE TEAM; ATABAK MOKARI JOINS AS CHIEF FINANCIAL OFFICER; CHARLES ROBB NAMED CHIEF BUSINESS OFFICER MENLO PARK, Calif. (March 1, 2021) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engage |
|
| February 23, 2021 |
Form of 2012 Incentive Award Plan Stock Option Grant Notice and Agreement EX-4.5 2 corts-8022321ex45.htm EX-4.5 Exhibit 4.5 EXHIBIT A TO STOCK OPTION GRANT NOTICE CORCEPT THERAPEUTICS INCORPORATED STOCK OPTION AGREEMENT Pursuant to the Stock Option Grant Notice (the “Grant Notice”) to which this Stock Option Agreement (this “Agreement”) is attached, Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), has granted to Participant an Option under the |
|
| February 23, 2021 |
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2020 AUDITED FINANCIAL RESULTS EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2020 AUDITED FINANCIAL RESULTS ?2020 revenue of $353.9 million, compared to $306.5 million in 2019 ?Fourth quarter revenue of $85.7 million, compared to $87.9 million in 2019 ?2020 GAAP net income of $106.0 million, compared to $94.2 million in 2019 ?Fourth quarter GAAP net income of $26.0 million, compared to $29.4 million i |
|
| February 23, 2021 |
Exhibit 4.2 DESCRIPTION OF COMMON STOCK The following description of Corcept?s common stock is a summary. This summary is subject to the General Corporation Law of the State of Delaware (the ?DGCL?) and the complete text of Corcept?s amended and restated certificate of incorporation (the ?certificate of incorporation?) and amended and restated bylaws (the ?bylaws?), filed as Exhibits 3.1 and 3.2, |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 23, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation o |
|
| February 23, 2021 |
As filed with the Securities and Exchange Commission on February 23, 2021 Registration No. |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCO |
|
| February 11, 2021 |
SC 13G 1 d107054dsc13g.htm SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Corcept Therapeutics Incorporated (Name of Issuer) Common Stock (T |
|
| February 10, 2021 |
SC 13G/A 1 tv0617-corcepttherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Corcept Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 218352102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 8, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| February 8, 2021 |
EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER, FULL-YEAR 2020 PRELIMINARY SELECTED FINANCIAL RESULTS AND 2021 REVENUE GUIDANCE; PROVIDES CORPORATE UPDATE Financial Highlights, 2021 Revenue Guidance and Legal Update •Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019 •Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 3, 2021 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| December 14, 2020 |
149 Commonwealth Drive. Menlo Park, CA 94025 . Tel 650.327.3270. Fax 650.327.3218 December 14, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| November 23, 2020 |
CORCEPT THERAPEUTICS APPOINTS GILLIAN M. CANNON, PHD, TO BOARD OF DIRECTORS EX-99.1 2 exhibit991pressrelease.htm EX-99.1 EXHIBIT 99.1 CORCEPT THERAPEUTICS APPOINTS GILLIAN M. CANNON, PHD, TO BOARD OF DIRECTORS MENLO PARK, Calif. (Nov. 23, 2020) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress |
|
| November 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 23, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation o |
|
| November 18, 2020 |
EXHIBIT 99.1 U.S. PATENT TRIAL AND APPEALS BOARD AFFIRMS VALIDITY OF ALL CLAIMS OF CORCEPT’S U.S. PATENT NO. 10,195,214 MENLO PARK, Calif. (November 18, 2020) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone c |
|
| November 18, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 18, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation o |
|
| November 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEU |
|
| November 3, 2020 |
Exhibit 10.1 SIXTH AMENDMENT SIXTH AMENDMENT (the "Sixth Amendment") is made and entered into as of July 22nd, 2020 by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the "Lease"), the first amendment (t |
|
| November 3, 2020 |
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (November 3, 2020) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, t |
|
| November 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 3, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| October 13, 2020 |
CORT / Corcept Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0014-corcepttherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Corcept Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 218352102 Date of Event Which Requires Filing of this Statement: September 30, 2020 Check the appropriate box |
|
| August 4, 2020 |
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (August 4, 2020) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, to |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 4, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or o |
|
| August 4, 2020 |
Exhibit 10.1 SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of August 3, 2020 (the “Effective Date”) is entered into by and between Hazel Hunt, Chief Scientific Officer (“CSO”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”). WITNESSETH: WHEREAS, CSO is a senior executive of the Company and is expected t |
|
| August 4, 2020 |
Exhibit 10.2 SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of August 3, 2020 (the “Effective Date”) is entered into by and between Joseph Douglas (“J.D.”) Lyon, Chief Accounting Officer (“CAO”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”). WITNESSETH: WHEREAS, CAO is a senior executive of the Company |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| August 4, 2020 |
Exhibit 10.3 SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of August 3, 2020 (the “Effective Date”) is entered into by and between Sean Maduck, Chief Commercial Officer (“CCO”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”). WITNESSETH: WHEREAS, CCO is a senior executive of the Company and is expected |
|
| August 4, 2020 |
Exhibit 10.4 FIFTH AMENDMENT THIS FIFTH AMENDMENT (the "Fifth Amendment") is made and entered into as of June 17, 2020 by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the "Lease") , the first amendmen |
|
| July 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 13, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or or |
|
| May 29, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 27, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or org |
|
| May 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 4, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or orga |
|
| May 4, 2020 |
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (May 4, 2020) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today |
|
| May 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| April 27, 2020 |
DEF 14A 1 a2020def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| April 9, 2020 |
CORT / Corcept Therapeutics, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment SC 13G/A 1 form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12*) CORCEPT THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 218352102 (CUSIP Number) March 31, 2020 (Date of Event Which |
|
| March 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 12, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or o |
|
| March 13, 2020 |
Corcept Therapeutics Appoints Gregg Alton to Board of Directors EXHIBIT 99.1 Corcept Therapeutics Appoints Gregg Alton to Board of Directors MENLO PARK, Calif. (March 12, 2020) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that former Gilead Sc |
|
| February 24, 2020 |
Exhibit 10.36 SECOND AMENDMENT THIS SECOND AMENDMENT (the “Second Amendment”) is made and entered into as of March 12, 2018 by and between Exponent Realty, LLC, a Delaware limited liability company (“Landlord”), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the “Lease”), and the first |
|
| February 24, 2020 |
As filed with the Securities and Exchange Commission on February 24, 2020 As filed with the Securities and Exchange Commission on February 24, 2020 Registration No. |
|
| February 24, 2020 |
Exhibit 10.35 FIRST AMENDMENT THIS FIRST AMENDMENT (the “Amendment”) is made and entered into as of June 1, 2017 by and between Exponent Realty, LLC, a Delaware limited liability company (“Landlord”), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the “Lease”). Pursuant to the Lease, L |
|
| February 24, 2020 |
Exhibit 10.37 THIRD AMENDMENT THIS THIRD AMENDMENT (the “Third Amendment”) is made and entered into as of November 8, 2018 by and between Exponent Realty, LLC, a Delaware limited liability company (“Landlord”), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the “Lease”), the first amen |
|
| February 24, 2020 |
Exhibit 10.34 OFFICE LEASE AGREEMENT by and between EXPONENT REALTY, LLC a Delaware limited liability company (“Landlord”) and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”) For approximately 20,831 rentable square feet at 149 Commonwealth Drive, Menlo Park, California (“Premises”) TABLE OF CONTENTS 1. Parties 3 2. Premises 3 3. Definitions 3 4. Lease Term 6 A. Term 6 B. Comm |
|
| February 24, 2020 |
Exhibit 4.2 DESCRIPTION OF COMMON STOCK The following description of Corcept’s common stock is a summary. This summary is subject to the General Corporation Law of the State of Delaware (the “DGCL”) and the complete text of Corcept’s amended and restated certificate of incorporation (the “certificate of incorporation”) and amended and restated bylaws (the “bylaws”), filed as Exhibits 3.1 and 3.2, |
|
| February 24, 2020 |
Exhibit 10.38 FOURTH AMENDMENT THIS FOURTH AMENDMENT (the “Fourth Amendment”) is made and entered into as of October 23, 2019 by and between Exponent Realty, LLC, a Delaware limited liability company (“Landlord”), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the “Lease”), the first a |
|
| February 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCO |
|
| February 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 20, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation o |
|
| February 20, 2020 |
EXHIBIT 99.1 Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update MENLO PARK, Calif. (February 20, 2020) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the st |
|
| February 14, 2020 |
SC 13G/A 1 corta221420.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CORCEPT THERAPEUTICS INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this St |
|
| February 14, 2020 |
CORT / Corcept Therapeutics, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment SC 13G/A 1 form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11*) CORCEPT THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2019 (Date of Event Whi |
|
| February 12, 2020 |
CORT / Corcept Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01035-corcepttherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Corcept Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 218352102 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box t |
|
| January 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 30, 2020 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| January 30, 2020 |
EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 PRELIMINARY SELECTED FINANCIAL RESULTS; PROVIDES 2020 REVENUE GUIDANCE • 2019 revenue of $306.5 million, an increase of 22 percent from 2018 • Fourth quarter revenue of $87.9 million, an increase of 32 percent from fourth quarter 2018 • Cash and investments at December 31, 2019, of $315.3 million • 2019 revenue guidance |
|
| November 7, 2019 |
Corcept Therapeutics Announces Third Quarter 2019 Financial Results and Provides Corporate Update EXHIBIT 99.1 Corcept Therapeutics Announces Third Quarter 2019 Financial Results and Provides Corporate Update MENLO PARK, Calif. (November 7, 2019) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, t |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 7, 2019 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation or |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEU |
|
| September 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 17, 2019 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation |
|
| September 18, 2019 |
CORCEPT THERAPEUTICS APPOINTS KIMBERLY PARK TO BOARD OF DIRECTORS EXHIBIT 99.1 CONTACT: Christopher S. James, MD Director, Investor Relations Corcept Therapeutics 650-684-8725 [email protected] www.corcept.com CORCEPT THERAPEUTICS APPOINTS KIMBERLY PARK TO BOARD OF DIRECTORS MENLO PARK, Calif. (September 18, 2019) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta |
|
| August 1, 2019 |
8-K 1 f8k080119.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 1, 2019 CORCEPT THERAPEUTICS INC (Exact Name of Registrant as Specified in Charter) Delaware 000-50679 77-0487658 (State or Other Jurisdiction of I |
|
| August 1, 2019 |
Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update EXHIBIT 99.1 Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormo |
|
| August 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS |
|
| June 20, 2019 |
Submission of Matters to a Vote of Security Holders 8-K 1 d765525d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 18, 2019 Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdict |
|
| June 11, 2019 |
8-K 1 d757669d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 11, 2019 Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other juri |
|
| May 9, 2019 |
10-Q 1 cort3311910-qdoc.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
